Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of hepatocellular carcinoma (HCC) by inducing meaningful rates of antitumor responses and having favorable toxicity profiles. Based on large, randomized phase III trials, including the IMbrave150 study testing atezolizumab plus bevacizumab vs sorafenib, combination ICI regimens have emerged as the preferred frontline treatments for HCC based on their overall survival (OS) benefit.1,2 HCC biology may be influenced by distinct etiologies underlying tumorigenesis including viral infections, alcohol-related injury, and metabolic causes.